Skip to main content

NCT00574288 - Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study


CSR Summary

Not Yet Available


Data Specification

Not Yet Available


Annotated CRF

Not Yet Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Daratumumab
Product Name
DARZALEX®
Therapeutic Area
Cancers and Other Neoplasms
Enrollment
106
% Female
31.7%
% White
N/A
Product Class
Monoclonal Antibody
Sponsor Protocol Number
54767414GEN501
Data Holder
Johnson & Johnson
Condition Studied
Multiple Myeloma
Mean/Median Age (Years)
61.4

Supporting Documentation

Annotated Case Report Form (CRF)
Clinical Study Report
Collected Datasets
Data Definition Specification
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.